J&J ends Actelion talks

Johnson & Johnson (NYSE:JNJ) said after market hours Tuesday that it "has ended discussions" with Actelion Ltd. (SIX:ATLN) about a potential deal. The pharma said the parties were unable to reach an agreement that J&J believed would "create adequate value" for shareholders.

Actelion acknowledged last month that J&J had approached it about a possible transaction (see BioCentury Extra, Nov. 28)...